NCT00948259 - Safety Study of a Glycogen Synthase Kinase 3 (GSK3) Inhibitor in Patients With Alzheimer´s Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions

Alzheimer´s Disease

Interventions

DRUG

NP031112

unidose sachets containing dry powder for oral suspension, once daily dosing 400 mg (4 to 20 weeks), 600 mg(4 to 16 weeks),800 mg (6 to 12 weeks), 1000 mg (6 weeks)

DRUG

Placebo

unidose sachets containing dry powder for oral suspension, once daily dosing 400 mg (4 to 20 weeks), 600 mg(4 to 16 weeks),800 mg (6 to 12 weeks), 1000 mg (6 weeks)

Trial Locations (3)

09111

Pharmacologische Studiecentrum Chemnitz, Chemnitz

0410Y

Arzneimittelforschung Leipzig GmbH, Leipzig

D- 90402

Studienzentrum PD Dr. Steinwachs, Nuremberg